Literature DB >> 33546704

The cancer metabolic reprogramming and immune response.

Longzheng Xia1, Linda Oyang1, Jinguan Lin1, Shiming Tan1, Yaqian Han1, Nayiyuan Wu1, Pin Yi1,2, Lu Tang1,2, Qing Pan1,2, Shan Rao1, Jiaxin Liang1, Yanyan Tang1, Min Su1, Xia Luo1, Yiqing Yang1, Yingrui Shi1, Hui Wang1, Yujuan Zhou3, Qianjin Liao4.   

Abstract

The overlapping metabolic reprogramming of cancer and immune cells is a putative determinant of the antitumor immune response in cancer. Increased evidence suggests that cancer metabolism not only plays a crucial role in cancer signaling for sustaining tumorigenesis and survival, but also has wider implications in the regulation of antitumor immune response through both the release of metabolites and affecting the expression of immune molecules, such as lactate, PGE2, arginine, etc. Actually, this energetic interplay between tumor and immune cells leads to metabolic competition in the tumor ecosystem, limiting nutrient availability and leading to microenvironmental acidosis, which hinders immune cell function. More interestingly, metabolic reprogramming is also indispensable in the process of maintaining self and body homeostasis by various types of immune cells. At present, more and more studies pointed out that immune cell would undergo metabolic reprogramming during the process of proliferation, differentiation, and execution of effector functions, which is essential to the immune response. Herein, we discuss how metabolic reprogramming of cancer cells and immune cells regulate antitumor immune response and the possible approaches to targeting metabolic pathways in the context of anticancer immunotherapy. We also describe hypothetical combination treatments between immunotherapy and metabolic intervening that could be used to better unleash the potential of anticancer therapies.

Entities:  

Keywords:  Immune checkpoint…; Immunity; Metabolic reprogramming; Oxysterols; TIL; TME

Year:  2021        PMID: 33546704     DOI: 10.1186/s12943-021-01316-8

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  140 in total

1.  Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.

Authors:  Binfan Chen; Ang Gao; Bin Tu; Yonghui Wang; Xiaolu Yu; Yingshu Wang; Yanfeng Xiu; Bing Wang; Yakun Wan; Yongzhuo Huang
Journal:  Biomaterials       Date:  2020-06-12       Impact factor: 12.479

2.  Toxohormone-like factor from microorganisms with impaired respiration.

Authors:  V CALLAO; E MONTOYA
Journal:  Science       Date:  1961-12-22       Impact factor: 47.728

Review 3.  Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy.

Authors:  Luana Guerra; Lynn Bonetti; Dirk Brenner
Journal:  Cell Rep       Date:  2020-07-07       Impact factor: 9.423

4.  Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target.

Authors:  Beatriz Lapa; Ana Cristina Gonçalves; Joana Jorge; Raquel Alves; Ana Salomé Pires; Ana Margarida Abrantes; Margarida Coucelo; Antero Abrunhosa; Maria Filomena Botelho; José Manuel Nascimento-Costa; Ana Bela Sarmento-Ribeiro
Journal:  Med Oncol       Date:  2020-07-28       Impact factor: 3.064

Review 5.  Metabolic pathways promoting cancer cell survival and growth.

Authors:  Lindsey K Boroughs; Ralph J DeBerardinis
Journal:  Nat Cell Biol       Date:  2015-03-16       Impact factor: 28.824

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 7.  Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities.

Authors:  Binlu Huang; Bao-Liang Song; Chenqi Xu
Journal:  Nat Metab       Date:  2020-02-10

Review 8.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

9.  1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis.

Authors:  Yutao Yan; Lei Chang; Hongzhe Tian; Lu Wang; Yawei Zhang; Tao Yang; Guohao Li; Weifeng Hu; Kavita Shah; Gang Chen; Yonglian Guo
Journal:  J Immunother Cancer       Date:  2018-12-13       Impact factor: 13.751

10.  Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer.

Authors:  Junfeng Zhang; Jianyu Yang; Chaoyi Lin; Wei Liu; Yanmiao Huo; Minwei Yang; Shu-Heng Jiang; Yongwei Sun; Rong Hua
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more
  44 in total

Review 1.  Tumor microenvironment metabolites directing T cell differentiation and function.

Authors:  Xia Liu; Daniel F Hoft; Guangyong Peng
Journal:  Trends Immunol       Date:  2021-12-29       Impact factor: 16.687

Review 2.  Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases.

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int Immunopharmacol       Date:  2022-06-28       Impact factor: 5.714

Review 3.  Arginase: Mechanisms and Clinical Application in Hematologic Malignancy.

Authors:  Zefan Du; Tianwen Li; Junbin Huang; Yun Chen; Chun Chen
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 4.  Aberrant lipid metabolism in cancer cells and tumor microenvironment: the player rather than bystander in cancer progression and metastasis.

Authors:  Xiujing Yu; Shuyi Mi; Jun Ye; Guochun Lou
Journal:  J Cancer       Date:  2021-11-04       Impact factor: 4.207

5.  CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.

Authors:  Lin Chen; Qiaodan Zhou; Junjie Liu; Wei Zhang
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 6.  The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.

Authors:  Bonnie L Russell; Selisha A Sooklal; Sibusiso T Malindisa; Lembelani Jonathan Daka; Monde Ntwasa
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

Review 7.  Neutrophil NETworking in ENL: Potential as a Putative Biomarker: Future Insights.

Authors:  Smrity Sahu; Keshav Sharma; Maryada Sharma; Tarun Narang; Sunil Dogra; Ranjana Walker Minz; Seema Chhabra
Journal:  Front Med (Lausanne)       Date:  2021-07-14

8.  A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma.

Authors:  Yue Li; Huanye Mo; Shengli Wu; Xin Liu; Kangsheng Tu
Journal:  Front Cell Dev Biol       Date:  2022-01-03

9.  Glutamine Metabolism Regulators Associated with Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis.

Authors:  Jingwen Zou; Kunpeng Du; Shaohua Li; Lianghe Lu; Jie Mei; Wenping Lin; Min Deng; Wei Wei; Rongping Guo
Journal:  Genes (Basel)       Date:  2021-08-25       Impact factor: 4.096

Review 10.  Cell Fate Reprogramming in the Era of Cancer Immunotherapy.

Authors:  Olga Zimmermannova; Inês Caiado; Alexandra G Ferreira; Carlos-Filipe Pereira
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.